有机化学 ›› 2019, Vol. 39 ›› Issue (4): 1029-1036.DOI: 10.6023/cjoc201811030 上一篇    下一篇

研究论文

含1H-苯并[d]咪唑或1H-苯并[d][1,2,3]三唑结构的新型查尔酮衍生物的合成及PTP1B抑制活性研究

付洋a,b, 盛丽c, 高立信c, 李佳c, 孙良鹏a   

  1. a 延边大学医学院 延吉 133002;
    b 中国科学院长春应用化学研究所 长春 130000;
    c 中国科学院上海药物研究所 国家新药筛选中心 上海 201203
  • 收稿日期:2018-11-26 修回日期:2018-12-21 发布日期:2019-01-10
  • 通讯作者: 李佳, 孙良鹏 E-mail:lpsun@ybu.edu.cn;jli@simm.ac.cn
  • 基金资助:

    国家自然科学基金(Nos.81460524,81773779)和吉林省教育厅"十二五"科学技术研究项目(No.2015-50)资助项目.

Synthesis and PTP1B Inhibitory Activity of Novel Chalcone Derivatives Bearing 1H-Benzo[d]imidazol or 1H-Benzo[d][1,2,3]triazol Moieties

Fu Yanga,b, Sheng Lic, Gao Lixinc, Li Jiac, Sun Liangpenga   

  1. a Medical College, Yanbian University, Yanji 133002;
    b Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130000;
    c National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203
  • Received:2018-11-26 Revised:2018-12-21 Published:2019-01-10
  • Contact: 10.6023/cjoc201811030 E-mail:lpsun@ybu.edu.cn;jli@simm.ac.cn
  • Supported by:

    Project supported by the National Natural Science Foundation of China (Nos.81460524,81773779) and the Scientific Research Fund Project of Education Department of Jilin Province (No.2015-50).

蛋白酪氨酸磷酸酶1B (PTP1B)作为胰岛素和瘦素信号转导通路的负调节因子,PTP1B抑制剂有希望成为治疗Ⅱ型糖尿病和肥胖症的候选药物.为了寻找非酸类PTP1B抑制剂,设计、合成了一系列含1H-苯并[d]咪唑或1H-苯并[d][1,2,3]三唑的查尔酮类化合物,并对化合物进行了PTP1B抑制活性测定.结果显示,所有化合物对PTP1B均显示出较强的抑制活性,其中2-(1H-苯并[d][1,2,3]三唑-1-基)-N'-(4-(3-(2'-萘基)-3-氧亚基-丙-1-烯基)苯亚甲基)乙酰肼(10i)活性最佳,IC50为(2.98±0.04)μmol·L-1.更重要的是,2-(1H-苯并[d][1,2,3]三唑-1-基)-N'-(4-(3-(4-甲基苯基)-3-氧亚基-丙-1-烯基)苯亚甲基)乙酰肼(10h)在20 μg/mL的浓度下对T细胞蛋白酪氨酸磷酸酶(TCPTP)没有活性,显示了较好的选择性.

关键词: PTP1B抑制剂, 1H-苯并[d]咪唑, 1H-苯并[d] [1,2,3]三唑, 查尔酮

Protein tyrosine phosphatase 1B (PTP1B) inhibitor has recently been identified as new candidate drug for type Ⅱ diabetes and obesity due to it is a negative regulator of the insulin and leptin-signaling pathway. In order to find new nonphosphonate-based pTyr mimetics, a series of novel chalcone derivatives bearing 1H-benzo[d]imidazol or 1H-benzo[d] [1,2,3]-triazol moieties were designed, synthesized, and evaluated for their PTP1B inhibitory activities. The results demonstrated that all compounds presented potent inhibitory activities against PTP1B, among which 2-(1H-benzo[d] [1,2,3]triazol-1-yl)-N'-(4-(3-(naphthalen-2-yl)-3-oxoprop-1-en-1-yl)benzylidene)acetohydrazide (10i) exhibited the best potency with IC50 value of (2.98±0.04) μmol·L-1. Importantly, 2-(1H-benzo[d] [1,2,3]triazol-1-yl)-N'-(4-(3-oxo-3-(p-tolyl)prop-1-en-1-yl)benzylidene)-acetohydrazide (10h) showed no significant inhibition on T-cell protein tyrosine phosphatase (TCPTP) at the concentration of 20 μg/mL, suggesting the highly selectivity of this agent toward PTP1B.

Key words: PTP1B inhibitor, 1H-benzo[d]imidazol, 1H-benzo[d] [1,2,3]triazol, chalcone